促红细胞生成素对慢性心功能不全合并贫血患者的疗效及安全性分析

目的 探讨促红细胞生成素对于慢性心功能能不全合并贫血患者的疗效及安全性.方法 慢性心功能能不全合并贫血患者66例,随机数字表法分为观察组和对照组.对照组采用常规抗心力衰竭治疗+铁剂抗贫血治疗,观察组在对照组治疗基础上,再予以促红细胞生成素治疗,两组患者均连续治疗8周.结果 治疗后,观察组患者心功能分级由(3.6±0.3)级改善为(1.6±0.2)级；对照组由(3.7±0.7)级改善为(2.8±0.4)级,观察组患者改善程度明显优于对照组患者；观察组患者的Hb、RBC、SV、CO较治疗前均有明显上升(均P ＜0.05),对照组治疗前后Hb、RBC、SV、CO水平均无明显变化；两组患者LVEF、FS均较治疗前有明显改善,但观察组患者改善程度明显优于对照组患者(P＜0.05).两组患者治疗前后E/A无明显变化.观察组和对照组患者药物不良反应发生率差异无统计学意义.结论 贫血程度直接影响到患者心脏功能的分级.在进行常规改善心功能不全治疗基础上,再予以促红细胞生成素治疗,可明显提高患者的治疗效果,且安全性较高.

Analysis of the efficacy and safety of erythropoietin for anemia in patients with chronic heart failure

Objective To analyze the efficacy and safety of erythropoietin for anemia in patients with chronic heart failure. Methods 66 cases with chronic heart failure were randomly divided into the observation group and the control group. The control group was treated with conventional anti-anemia iron treatment, and the observation group was taken erythropoietin therapy treatment on the basis of the control group. Both of the two groups were treated for 8 weeks continuously. Results There were statistically significant differences between the two groups of patients after 8 weeks of treatment, cardiac function had improvement after treatment than before treatment （P 〈 0.05 ）. The observation group was significantly superior than the control group. The blood data in the two groups were compared,the Hb, RBC of the observation group were significantly increased compared with before treatment, the difference was significant （P 〈 0.05 ）. The RBC level did not change significantly in the control group before and after treatment. The electronic patient data in the two groups were compared, the LVEF, FS in the observation group and control group improved significantly compared with before treatment, but improvement of the observation group was significantly better than control group. The degree of improvement in the two groups were compared, the difference was significant （ P 〈 0. 05 ）. The SV, CO in the two groups were compared, it increased significantly than before treatment, the difference was significant（P 〈 0.05）. The SV, CO before and after treatment in the control group didn＇t improve significantly. The E/A before and after treatment didn＇t improve significantly. The incidence of adverse drug reactions in the two groups showed no significant difference. Conclusion The level of anemia had a direct impact on the degree of heart function classification. Following the usual treatment of heart failure, taking erythropoietin for anemia in patients with chronic heart treatment could significantly improve the treatment of patients with curative effect, with the advantages of safe, widely used for clinical application.